These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

409 related items for PubMed ID: 31841388

  • 1. Effects of a prolyl hydroxylase inhibitor on kidney and cardiovascular complications in a rat model of chronic kidney disease.
    Uchida L, Tanaka T, Saito H, Sugahara M, Wakashima T, Fukui K, Nangaku M.
    Am J Physiol Renal Physiol; 2020 Feb 01; 318(2):F388-F401. PubMed ID: 31841388
    [Abstract] [Full Text] [Related]

  • 2. Prolyl Hydroxylase Domain Inhibitor Protects against Metabolic Disorders and Associated Kidney Disease in Obese Type 2 Diabetic Mice.
    Sugahara M, Tanaka S, Tanaka T, Saito H, Ishimoto Y, Wakashima T, Ueda M, Fukui K, Shimizu A, Inagi R, Yamauchi T, Kadowaki T, Nangaku M.
    J Am Soc Nephrol; 2020 Mar 01; 31(3):560-577. PubMed ID: 31996409
    [Abstract] [Full Text] [Related]

  • 3. JTZ-951 (enarodustat), a hypoxia-inducibe factor prolyl hydroxylase inhibitor, stabilizes HIF-α protein and induces erythropoiesis without effects on the function of vascular endothelial growth factor.
    Fukui K, Shinozaki Y, Kobayashi H, Deai K, Yoshiuchi H, Matsui T, Matsuo A, Matsushita M, Tanaka T, Nangaku M.
    Eur J Pharmacol; 2019 Sep 15; 859():172532. PubMed ID: 31301309
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Prolyl hydroxylase inhibition protects the kidneys from ischemia via upregulation of glycogen storage.
    Ito M, Tanaka T, Ishii T, Wakashima T, Fukui K, Nangaku M.
    Kidney Int; 2020 Apr 15; 97(4):687-701. PubMed ID: 32033782
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Prolyl Hydroxylase Inhibitors: a New Opportunity in Renal and Myocardial Protection.
    Requena-Ibáñez JA, Santos-Gallego CG, Rodriguez-Cordero A, Zafar MU, Badimon JJ.
    Cardiovasc Drugs Ther; 2022 Dec 15; 36(6):1187-1196. PubMed ID: 34533692
    [Abstract] [Full Text] [Related]

  • 12. The balance of beneficial and deleterious effects of hypoxia-inducible factor activation by prolyl hydroxylase inhibitor in rat remnant kidney depends on the timing of administration.
    Yu X, Fang Y, Liu H, Zhu J, Zou J, Xu X, Jiang S, Ding X.
    Nephrol Dial Transplant; 2012 Aug 15; 27(8):3110-9. PubMed ID: 22399494
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Preconditioned suppression of prolyl-hydroxylases attenuates renal injury but increases mortality in septic murine models.
    Schindler K, Bondeva T, Schindler C, Claus RA, Franke S, Wolf G.
    Nephrol Dial Transplant; 2016 Jul 15; 31(7):1100-13. PubMed ID: 26908768
    [Abstract] [Full Text] [Related]

  • 16. Inhibition of prolyl hydroxylase domain-containing protein on hypertension/renal injury induced by high salt diet and nitric oxide withdrawal.
    Dallatu MK, Choi M, Oyekan AO.
    J Hypertens; 2013 Oct 15; 31(10):2043-9. PubMed ID: 23811999
    [Abstract] [Full Text] [Related]

  • 17. Enarodustat to treat anemia in chronic kidney disease.
    Fukui K, Tanaka T, Nangaku M.
    Drugs Today (Barc); 2021 Aug 15; 57(8):491-497. PubMed ID: 34405206
    [Abstract] [Full Text] [Related]

  • 18. Hypoxia-inducible factor-prolyl hydroxylase inhibitor ameliorates myopathy in a mouse model of chronic kidney disease.
    Qian FY, Li ZL, Guo YD, Gao HC, Gu LH, Le K, Xie CM, Wang B, Zhang ZJ.
    Am J Physiol Renal Physiol; 2019 Nov 01; 317(5):F1265-F1273. PubMed ID: 31588798
    [Abstract] [Full Text] [Related]

  • 19. The prolyl 4-hydroxylase inhibitor GSK360A decreases post-stroke brain injury and sensory, motor, and cognitive behavioral deficits.
    Zhou J, Li J, Rosenbaum DM, Zhuang J, Poon C, Qin P, Rivera K, Lepore J, Willette RN, Hu E, Barone FC.
    PLoS One; 2017 Nov 01; 12(9):e0184049. PubMed ID: 28880966
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 21.